HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Half Of All OTCs Could Disappear From Northern Ireland Under Current Brexit Rules

Executive Summary

UK consumer healthcare association chief Michelle Riddalls tells House of Lords peers that over half of OTC medicines could disappear from Northern Ireland's pharmacy and grocery shelves because of regulatory burdens imposed by the Brexit-related Northern Ireland Protocol. 

You may also be interested in...



UK Industry Welcomes Post-Brexit ‘Windsor Framework’ For Northern Ireland

UK consumer healthcare industry association, PAGB, has welcomed the landmark “Windsor Framework” agreed by the UK and the EU, which proposes that medicines will take a “green lane” from Great Britain to Northern Ireland, while the UK regulator, MHRA, will have UK-wide responsibility for all drug approvals.

If Successful, HRA Pharma Acquisition Will Complete Perrigo’s Pivot Towards Self-Care

If its acquisition of France's HRA Pharma completes, Perrigo will have “enough growth in our back pocket for the next three to five years without making any further acquisitions,” says the firm’s UK & Ireland chief, Neil Lister, in an exclusive interview with HBW Insight. 

EU OTC Batch Testing Will Continue To Be Accepted In UK, For Now

Recognition of EU/EEA batch testing of imported medicines by UK will not be ending on 1 January 2023, and companies will be given two years notice if anything changes, says MHRA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel